PRELIMINARY RESULTS Investor Presentation Year ended 30 June 2017
|
|
- Fay Lamb
- 6 years ago
- Views:
Transcription
1 PRELIMINARY RESULTS Investor Presentation Year ended 30 June 2017
2 Disclaimer This presentation has been prepared by Genus ( Genus or the Company ) and has not been independently verified. Genus is solely responsible for the contents of this document and has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects and that there are no material facts the omission of which would make misleading any statement in this document whether of fact or opinion. While the information contained in this presentation has been provided in good faith, neither the Company, nor any of their advisers, representatives, officers, agents or employees makes any representation, warranty or undertaking, express or implied, in respect of this presentation and no responsibility or liability is accepted by any of them as to the accuracy, completeness or reasonableness of the information provided. The issue of this presentation to the recipient does not create any obligation on the part of the issuer to provide the recipient access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in this presentation or any additional information which may become apparent. The recipient should conduct its own investigation into the Company and of any other information contained in the presentation. This presentation is for information purposes only and does not constitute, and shall not be interpreted as, either an offer for sale, prospectus, invitation to subscribe for shares or debentures in the Company, or as the basis of a contract. This presentation has been prepared on the basis that it will only be made available to investment professionals and is thereby exempt from the provisions of s21 of the Financial Services and Markets Act
3 Overview Bob Lawson Chairman 3
4 Strong strategic progress and solid financial results > Results in line with expectations Profit before tax up 13% (1% lower in constant currency) Strong free cash flow Earnings per share 69.4p, up 14% (unchanged in constant currency) > Strong strategic progress Hermitage agreement and growing PIC royalties Gene editing progress Sexcel launched > Dividend increased 10% to 23.6p per share 4
5 Financial results Stephen Wilson Finance Director 5
6 Results Year ended 30 June 2017 % Change Actual m m Currency Constant Currency Revenue % 6% Adjusted operating profit % (1)% Attributable to non-controlling interest (2.1) (1.4) (50)% (19)% Adjusted share of JV profits % (10)% Adjusted operating profit (inc JV) % (2)% Finance costs (3.7) (4.6) 20% 18% Adjusted profit before tax % (1)% Adjusted earnings per share (pence) % - Dividend per share (pence) % 6
7 Volume growth Year ended 30 June 2017 Porcine Volume growth (%) 10% Dairy & Beef Volume growth (%) 6% 8% 6% 4% 2% 5% 9% 6% 4% 4% 4% 2% 0% (2%) (4%) 6% 5% 5% 1% (6%) 0% (6%) 7
8 Adjusted operating profit by business unit Year ended 30 June m 2016 m Actual Currency % Change Constant Currency Genus PIC % 7% Genus ABS (3)% (13)% Operating units % 2% Research and Development (43.8) (34.4) (27)% (12)% Central costs (12.2) (11.3) (8)% 5% Adjusted operating profit inc JV % (2)% > Asia now included in global PIC and ABS business units 8
9 Genus PIC Year ended 30 June 2017 % Change 2017 m 2016 m Actual Currency Constant Currency* Revenue % 7% Adjusted operating profit exc JV % 8% Adjusted operating profit inc JV % 7% Adjusted operating margin exc JV 35.2% 34.6% 0.6pts 0.3pts > Continued growth in profit up 7% and royalty revenues up 5% Volumes up 4%, with 77% under royalty (+1 pt, +3 pts excluding China) > Overall volumes unchanged in North America and Latin America Significant new stockings in North America support future royalty growth Latin America; strong profit performance in Mexico (+11%) offsets impact of instability in Venezuela > Europe profit up 26% from royalty growth and business transformation Hermitage initial contribution encouraging > Asia volumes up 20% and profit up 60% with growth in all countries Strong product performance in buoyant market helped China to 80%+ profit growth * All % changes are in constant currency unless otherwise stated 9
10 Genus ABS Year ended 30 June 2017 % Change 2017 m 2016 m Actual Currency Constant Currency* Revenue % 2% Adjusted operating profit (4)% (15)% Adjusted operating profit less NCI** (3)% (13)% Adjusted operating margin 11.4% 13.5% (2.1)pts (2.1)pts > ABS volumes up 1% with stronger second-half performance (+8%) in improving markets Strong sexed volume growth of 10%, beef volumes 3% lower in challenging markets > Europe volumes up 6% and profit up 8% benefiting from actions taken in 2016 and 2017 > Latin America profit up 41% with continued action to increase prices (+11%) Volumes 2% lower primarily due to weak beef markets > North America profit down 12%, including impact from weaker beef markets Focus on improving commercial execution in large dairy enterprises > Double digit volume growth in IVB driven by US; strong first year in Mexico Remaining 49% shares of IVB acquired ahead of schedule * All % changes are in constant currency unless otherwise stated ** NCI = Non-controlling Interest 10
11 Genus R&D Year ended 30 June m 2016 m Actual Currency % Change Constant Currency* Gene editing % 251% Other research % 2% Porcine product development % 7% Bovine product development % 6% Research and Development inc NCI** % 12% > Gene editing investment of 3.5m as planned PRRSv programme platform capability build; pregnancies for first generation of gene edited pigs created > Other research up 2%; continued activities in genomic evaluation, core informatics and IP > Porcine product development up 7% Increased spend from lower by-product market prices and increased animal volumes > Bovine product development up 6% GSS manufacturing and launch preparation costs in excess of 2m partially offset by efficiencies in bull development costs through De Novo and other initiatives * All % changes are in constant currency unless otherwise stated ** NCI = Non-controlling Interest 11
12 Statutory income statement Year ended 30 June Variance m m m Adjusted operating profit exc JV Net IAS 41 valuation movement (1.1) (17.1) 16.0 Amortisation of intangibles (8.7) (6.1) (2.6) Share-based payments (4.6) (3.8) (0.8) Exceptional items - Pension related (38.5) - Litigation (5.3) (6.9) Acquisition and integration (0.6) (0.2) (0.4) - Other (including restructuring) (2.3) (0.8) (1.5) Operating profit (20.4) - Share of post-tax profit of JVs (0.7) - Net finance costs (3.7) (4.6) 0.9 Profit before tax (20.2) 12
13 Cash flow Year ended 30 June Variance m m m Adjusted operating profit exc JV Depreciation and amortisation Adjusted EBITDA Working capital (1.1) 1.1 (2.2) Biological assets (5.7) (3.8) (1.9) Pension deficit repair, exceptionals and other (13.5) (11.7) (1.8) Net cash inflow from operating activities Cash conversion % 84% 88% (4)Pts Interest and tax paid (11.7) (13.3) 1.6 Capital expenditure (18.9) (18.6) (0.3) Cash received from joint ventures Other Free cash flow Acquisitions and investments (30.0) (7.2) (22.8) Dividends (13.5) (12.2) (1.3) Net cash flow (18.1) (3.7) (14.4) Net Debt
14 Strong financial position Year ended 30 June m m Owners equity Net Debt Key Financial ratios: - Return on adjusted capital 19.9% 19.1% - Gearing 28% 24% - Net debt to EBITDA 1.5x 1.4x - Interest cover 37x 35x - Dividend cover 2.9x 2.8x > Dividend up 10% > 74m headroom on bank facilities 14
15 Business update Karim Bitar Chief Executive 15
16 Strong strategic progress > ABS Leveraging De Novo, launching Sexcel, growing IVB Improving commercial execution Launching NuEra proprietary beef genetics > PIC Growing in key markets and segments, particularly in China Hermitage integration and partnership on track > R&D Continuing to strengthen proprietary technology platform 16
17 Strengthening competitive position and execution focus Dairy Strategic progress Leveraging competitive strengths Managing performance More focused execution under new leadership Making own genetics Sexing with proprietary technology NORTH AMERICA Implementing turnaround Growing IVB USA EMEA Improved volume and performance Growing product offering Producing embryos with our sexed genetics LATIN AMERICA Improved value capture Strong start for IVB Mexico Geographical split indicative of internal segmentation of territories not all countries shown are served by ABS ASIA China: Growing direct business India: Producing elite genetics, strengthening indirect channel 17
18 Genus ABS launches Sexcel September 1 st,
19 Sexcel launch customer field trial experience Dairy Bottom line, it gets heifers pregnant. No matter what you re dealing with. No matter what time of year you re breeding US customer I am very impressed with my experience with Sexcel we have seen an 8% increase in conception rates UK customer ABS genetics in Sexcel gives me confidence in the future animals that will enter into my herd Italian customer 19
20 Strategic progress in India Dairy ABS STRYKER #1 Holstein bull in India ABS TYSON #1 Jersey bull in India ABS REDHU #1 Murrah bull in India Producing India s leading temperate and indigenous genetics locally Sexing temperate and indigenous genetics locally with our proprietary sexing technology 20
21 Strong IVB performance Dairy Beef 100% Genus ownership of IVB to further accelerate growth Growing presence with large enterprise dairies in the US and Latin America >100% Volume growth in IVB USA Volume growth refers to embryos produced by IVB in the US 21
22 Launching NuEra proprietary beef genetics Beef Efficiency, Profitability, Sustainability Creating value for our customers......through proprietary genetic improvement focusing on key markets and segments Product focus on customer profitability, not breeds, proven through trials Breeding proprietary animals to profit-focused indices Serving progressive beef & dairy herds with terminal beef and cross-bred genetics 22
23 PIC continues to deliver strategic growth Pork North America % volumes under royalty 96% 96% 96% 97% % volumes under royalty EMEA Three new top 20 North American accounts won FY14 FY15 FY16 FY17 59% 64% 63% 38% FY14 FY15 FY16 FY17 Key account growth in Spain Hermitage growth Latin America Asia Key account growth in Brazil Developing Colombian franchise business % volumes under royalty 65% 64% 73% 77% % volumes under royalty 46% 35% 41% 50% China: Three new royalty customers Royalty growth in Russia and the Philippines FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 Volumes based on market pig equivalents; geographical split indicative of internal segmentation of territories not all countries shown are served by PIC 23
24 Hermitage integration on track Pork Integrating genetic programmes Strategic partnership multiplication, distribution Growing with key customers > Integrating Hermitage genes into PIC gene pool > Customers to access stronger products > Hermitage distributing PIC genetics under royalty in key markets > Hermitage producing PIC genetics under contract > Growing key account presence in Europe > Successfully transitioned key customer relationships 24
25 China aligning with our global business model and performing strongly Pork Supply chain Royalty customers 100% 90% 23% 24% 25% 13,770 16,000 14,000 Previous FY17+ 80% 70% 60% 50% 40% 100% 51% 54% 8,270 7,900 8,650 49% 8,305 48% 45% 7,970 62% 12,000 10,000 8,000 6,000 30% 20% 10% 0% 49% 46% 26% 2,970 28% 28% 30% 12% FY12 FY13 FY14 FY15 FY16 FY17 FY18(F) 4,000 2,000 0 Owned JV Multiplication GGPs TOTAL > Growing our overall capacity > Three new royalty customers > Continuing to transition production to contracted multiplication > Trebled royalty income in FY17 Note: FY17+ customers includes one customer signed in July 2017; royalty customer map shows operational location for 8 royalty customers in total 25
26 Genus strategy Dairy Pork Beef GENETIC IMPROVEMENT SHARED PROPRIETARY TECHNOLOGY PLATFORM GENOMIC SELECTION BIOSYSTEMS ENGINEERING GENOME SCIENCE GENE EDITING 26
27 Genomic selection: delivering continuous improvement Pork PIC Genetic Index Dairy Source of new Holstein bulls in the US Beef Relationship based genomic selection starts 1% 20% 23% ~40% FY15 FY16 FY17 FY18(F) ABS Internal/ De Novo Independent breeders > DNA-based selection continues to deliver > Integration of Hermitage genes underway > De Novo one year in: ~trebled size of ABS breeding programme > De Novo consistently producing high quality genetics > New global brand for proprietary beef offering > New tailored indices and Beef x Dairy products supporting price-to-value initiatives 27
28 PRRSv resistance progress FY16 0.9m expense FY17 3.5m expense CD163 IP licence Gene editing company co-founded Molecular scissor IP licence Molecular scissors optimised for CD163 Molecular scissor optimisation work begins Building regulatory capability US FDA - INAD issued First pregnant sows carrying edited embryos The PRRSv programme is an investigational programme relating to resistance to Porcine Reproductive and Respiratory Syndrome Virus; INAD refers to Investigational New Animal Drug application with the US Food and Drug Administration for the investigational PRRSv programme. The information included on this page reflects Genus plc s research and development pipeline and is not intended for promotional purposes. All timing, including any relevant regulatory approvals, are purely indicative, and any regulatory approvals are subject to the success of ongoing research, the development of clear regulatory review pathway by the relevant regulatory authorities and the approval by the regulators of any new animal drug application. 28
29 Launch Regulatory Technical & operational Technology Development programme for PRRSv resistance CD163 IP licence Molecular scissor technology licence Yrs 1-2 Yrs 2-5 Yrs 5+ Scissors optimised for CD163 edit Creating founder animals Amplify founder animals by breeding Development stage testing US FDA INAD issued Prepare and submit key country regulatory dossiers Regulatory approvals current Scale & launch The PRRSv programme is an investigational programme relating to resistance to Porcine Reproductive and Respiratory Syndrome Virus; INAD refers to Investigational New Animal Drug application with the US Food and Drug Administration for the investigational PRRSv programme. The information included on this page reflects Genus plc s research and development pipeline and is not intended for promotional purposes. All timing, including any relevant regulatory approvals, are purely indicative, and any regulatory approvals are subject to the success of ongoing research, the development of clear regulatory review pathway by the relevant regulatory authorities and the approval by the regulators of any new animal drug application. 29
30 Summary and outlook > ABS Leveraging De Novo, launching Sexcel, growing IVB Improving commercial execution Launching NuEra proprietary beef genetics > PIC Growing in key markets and segments, particularly in China Hermitage integration and partnership on track > R&D Continuing to strengthen proprietary technology platform > Expect to perform in line with our expectations for FY18 30
31 Appendices 31
32 Market dynamics output prices 50 Dairy - Key Markets (Pence per litre) 3.5 Pork - Key Markets ( per kg) China India Russia Brazil EU US China EU Russia Brazil US 15 Aug 14 Aug 15 Aug 16 Aug 17 SOURCE: Genus analysis using constant currency 0.5 Aug 14 Aug 15 Aug 16 Aug 17 32
33 SOURCE: Genus analysis using constant currency Market dynamics - input costs LIFFE Wheat and CBOT Soybean ( per tonne) Corn - Key Markets ( per tonne) CBOT Soybean China LIFFE Wheat EU US Brazil Aug 14 Aug 15 Aug 16 Aug 17 0 Aug 14 Aug 15 Aug 16 Aug 17 33
34 Return on adjusted capital Year ended 30 June m m Adjusted operating profit inc JV Tax rate 25.0% 25.8% Adjusted operating profit after tax Equity attributable to owners of the company Add back : Net debt Pension liability Related deferred tax (8.5) (9.6) Deduct : Biological assets (less historic cost) (323.8) (311.9) Goodwill (104.7) (86.0) Related deferred tax Adjusted invested capital Return on adjusted invested capital 19.9% 19.1% 34
35 Exchange rate sensitivity > Genus geographic profile can lead to translational currency impacts > We monitor key rates against GBP > Latest spot rates would indicate a 0-1m gain for FY18 compared with average FY17 rates FY17 FY17 Profit Average Closing 04 Sep 17 Sensitivity m* US Dollar Euro Brazilian Real Mexican Peso Chinese Yuan Russian Rouble * - 12 month operating profit impact given a +/- 10% movement in exchange rate, based on FY17 results
Genus plc PRELIMINARY RESULTS
Genus plc PRELIMINARY RESULTS Year Ended 30 June 2008 16 September 2008 Disclaimer This presentation has been prepared by Genus ( Genus or the Company ) and has not been independently verified. Genus is
More informationGenus, a leading global animal genetics company, announces its unaudited interim results for the six months ended 31 December 2017.
Immediate 28 February 2018 Genus plc ( Genus, the Company or the Group ) INTERIM RESULTS FOR THE SIX MONTHS ENDED DECEMBER STRONG FINANCIAL PERFORMANCE AND STRATEGIC PROGRESS Genus, a leading global animal
More informationPIONEERING ANIMAL GENETIC IMPROVEMENT
PIONEERING ANIMAL GENETIC IMPROVEMENT Genus plc Annual Report A WORLD LEADER IN ANIMAL GENETIC IMPROVEMENT GENUS HELPS FARMERS TO PRODUCE HIGH-QUALITY MEAT AND MILK MORE EFFICIENTLY AND SUSTAINABLY, WHICH
More informationAegis Group plc Half Year Results. 27 August 2010
Aegis Group plc 2010 Half Year Results 27 August 2010 Agenda Introduction John Napier, Chairman Aegis Group overview Jerry Buhlmann, CEO Divisional review Aegis Media - Jerry Buhlmann, CEO Synovate Robert
More informationResults presentation For the year ending 31 December 2015
Results presentation For the year ending 31 December 2015 1 Results Presentation March 2016 Agenda 1 2015 Overview & Business Priorities Update Chris Weston, CEO 2 2015 Financial & Operating Review Carole
More informationAEGIS GROUP PLC 2008 ANNUAL RESULTS. 19 March 2009
AEGIS GROUP PLC 2008 ANNUAL RESULTS 19 March 2009 AGENDA OVERVIEW OF RESULTS John Napier FINANCIAL REVIEW Alicja Lesniak OUTLOOK John Napier Q&A Aegis Group plc Page 2 OVERVIEW OF RESULTS John Napier,
More informationJohn Menzies plc. Interim Results Presentation 14 August 2018
John Menzies plc Interim Results Presentation 14 August 2018 Results Overview Highlights Underlying operating profit at 33.9m, up 18% at constant currency Profit progression John Menzies plc H1 underlying
More informationHalf-year results July 27, 2017 Nestlé half-year results 2017
Half-year results 2017 1 Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements involve certain risks and
More informationINTERIM RESULTS 2015 FOR THE SIX MONTHS ENDING 30th JUNE 2015
INTERIM RESULTS 2015 FOR THE SIX MONTHS ENDING 30th JUNE 2015 INTERIM RESULTS 2015 HIGHLIGHTS Organic revenue growth of 2%, lower than recent years as a result of: - Shift in phasing of revenues and trading
More informationJuly 26, 2017 LafargeHolcim Ltd 2015
Second Quarter 2017 Results Beat Hess, Chairman and Interim CEO Roland Köhler, Interim COO and Regional Head of Europe, Australia/NZ & Trading Ron Wirahadiraksa, CFO July 26, 2017 LafargeHolcim Ltd 2015
More informationCroda International Plc 2014 Interim Results. 22 July 2014
Croda International Plc 2014 Interim Results 22 July 2014 Introduction Steve Foots Group Chief Executive Underlying progress in a tough environment Constant currency turnover up 2.3% 5 out of 8 core markets
More informationAegis Group plc. 17 March 2011
Aegis Group plc 2010 Full Year Results 2010 Full Year Results 17 March 2011 Agenda Introduction John Napier, Chairman Aegis Group overview Jerry Buhlmann, CEO Divisional review Aegis Media - Jerry Buhlmann,
More information2011 Full Year Results
2011 Full Year Results Basel: February 8, 2012 Safe harbor This document contains forward-looking statements, which can be identified by terminology such as expect, would, will, potential, plans, prospects,
More informationCroda International Plc 2013 Preliminary Results. 25 February 2014
Croda International Plc 2013 Preliminary Results 25 February 2014 Introduction Steve Foots Group Chief Executive Robust results in a tough environment Profit before tax 1 up 5.4% to 251.4m Earnings per
More informationIMI plc 2018 Preliminary Results
IMI plc 2018 Preliminary Results 1 Agenda Highlights Lord Smith of Kelvin Chairman Financial review Daniel Shook Finance Director Operational review Mark Selway Chief Executive Q&A IMI Executive Team 2
More informationSegmental operating profit 227.7m Down 17% 1. Reported earnings per share 59.8p Down 4%
Highlights Revenue 1,649m Down 5% 1 Segmental operating profit 227.7m Down 17% 1 Segmental operating margins 13.8% Down 160bps Operating cash flow 2 246m Up 6% Reported earnings per share 59.8p Down 4%
More informationInvestor & Analyst Presentation Ful YearResults 30 June2016 For personal use only 25th August 2016 Rebekah O Flaherty - CEO I Jonathan Kenny - CFO
Investor & Analyst Presentation Full YearResults 30 June2016 25th August 2016 Rebekah O Flaherty - CEO I Jonathan Kenny - CFO Agenda 1 Overview 2 Strategic Priorities 3 FY16 Financial Results 4 FY17 Outlook
More informationIncome taxes (excluding non-trading items) (89.2) (89.5)
FINANCIAL REVIEW Delivering another year of solid performance + Group Key Performance Indicators pages 30-31 Financial Statements pages 138-202 The Group delivered another year of solid performance against
More informationSABMiller plc. Full year results Twelve months ended 31 March Graham Mackay, Chief Executive Jamie Wilson, Chief Financial Officer.
SABMiller plc Full year results Twelve months ended 31 March 2012 Graham Mackay, Chief Executive Jamie Wilson, Chief Financial Officer 24 May 2012 Forward looking statements This presentation includes
More informationAccelerating our IPT strategy
Accelerating our IPT strategy GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Transaction lays foundation for separation of GSK to create two new UK-based
More informationPreliminary Results for year ended 30 November 2015
Preliminary Results for year ended 30 November 2015 Good progress against a challenging market backdrop 5 year planning process completed, underpins 2016 expectations Clear long term strategy being implemented
More information2 AUGUST Results. Presentation. For the half year ending 30 June Results Presentation August 2017
2 AUGUST 2017 Results Presentation For the half year ending 30 June 2017 1 Chris Weston CEO 2 Agenda 1H17 Operating & Financial Review and Outlook Carole Cran, CFO Market Overview Chris Weston, CEO 3 The
More informationDatatec Group Audited results for the year ended 29 February 2008
Datatec Group Audited results for the year ended 29 February 2008 1 Datatec Group Highlights Revenue up 27% (12.2% organic) to over $4.0 billion Improved geographic spread of business helps to mitigate
More informationBUILDING A BOLD AND SUSTAINABLE FUTURE
BUILDING A BOLD AND SUSTAINABLE FUTURE 2018 HALF YEAR RESULTS 7 AUGUST 2018 PRESENTED BY: CHAIRMAN MARTIN LAMB CHIEF EXECUTIVE KEVIN HOSTETLER FINANCE DIRECTOR JONATHAN DAVIS Keeping the World Flowing
More informationAnpario plc (AIM: ANP) Financial and operational highlights. Financial highlights. Operational highlights
Interim Report 2017 Anpario plc (AIM: ANP) 19 September 2017 Anpario plc, the international producer and distributor of natural animal feed additives for animal health, nutrition and biosecurity is pleased
More informationDisclaimer: Forward Looking Statements
20 February 2018 Disclaimer: Forward Looking Statements This presentation/announcement may contain forward looking statements with projections regarding, among other things, the Group s strategy, revenues,
More informationRELX Group interim results 2017 Erik Engstrom, CEO Nick Luff, CFO
RELX Group interim results Erik Engstrom, CEO Nick Luff, CFO FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the US Securities Act
More informationSABMiller plc US annual results presentation Year ended March 31, 2014
SABMiller plc US annual results presentation Year ended March 31, 2014 Presented by Jamie Wilson, Chief Financial Officer Gary Leibowitz, SVP Internal & Investor Engagement Forward looking statements This
More information2015 Half-Year Results. François-Xavier Roger Chief Financial Officer
2015 Half-Year Results François-Xavier Roger Chief Financial Officer Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward
More informationInterim Results FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016
Interim Results FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016 1 AGENDA INTRODUCTION Martin Davey, Chairman HIGHLIGHTS Adam Couch, CEO FINANCIAL REVIEW Mark Bottomley, Finance Director COMMERCIAL REVIEW Jim
More information2015 Half Year Results Strongly improved free cash flow, on track to achieve 2015 targets. 17 July 2015
Strongly improved free cash flow, on track to achieve 2015 targets 17 July 2015 Gilles Andrier Chief Executive Officer 2 Financial highlights Sales of CHF 2.2 billion, up 1.3% on a like-for-like* basis
More informationBBA Aviation. BBA Aviation 2017 Final Results
BBA Aviation 2017 Strong execution in favourable market conditions Signature Significant progress on the commercial renegotiations Unique global network of 198 FBOs Investing for future growth Signature
More informationNufarm Interim Results
Nufarm Interim Results 6 months to January 31, 2018 March 21, 2018 1 Disclaimer General This presentation has been prepared by Nufarm Limited. The information contained in this presentation is for informational
More informationZEBRA TECHNOLOGIES FIRST QUARTER 2016 RESULTS May 10, 2016
ZEBRA TECHNOLOGIES FIRST QUARTER 2016 RESULTS May 10, 2016 Anders Gustafsson Chief Executive Officer Mike Smiley Chief Financial Officer 2 Safe Harbor Statement Statements made in this presentation which
More informationFY 2017 Results. March 6, 2018
FY 2017 Results March 6, 2018 Forward looking statements This Presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management s current
More information2018 Half Year Results
A GLOBAL LEADER IN METAL FLOW ENGINEERING 2018 Half Year Results 26 July 2018 Patrick André Chief Executive 1 Disclaimer This presentation, which has been prepared by Vesuvius plc (the Company ), includes
More informationCover-More Group. UBS Australasia Conference. November 2015
Cover-More Group UBS Australasia Conference November 2015 Executive summary: FY15 overview Cover-More delivered another year of double digit earnings growth, with offshore business growing substantially.
More informationH1 16 interim results. 22 September 2015
H1 16 interim results 22 September 2015 Important notice 2 This presentation may include certain forward-looking statements, beliefs or opinions, including statements with respect to the Company s business,
More informationH RESULTS PRESENTATION
H1 2018 RESULTS PRESENTATION 03.09.2018 H1 2018 RESULTS PRESENTATION DISCLAIMER This presentation (the "Presentation") has been prepared and is issued by, and is the sole responsibility of Telepizza Group,
More informationStrong performance in a challenging environment
Investor Relations News February 20, 2014 Henkel delivers on 2013 financial targets Strong performance in a challenging environment Solid organic sales growth of 3.5% Sales impacted by foreign exchange
More informationInterim Report Q3 2018
Interim Report Q3 2018 4 A KEY FIGURES Q3 Key Figures Group amounts in millions Q3 2018 Q3 2017 % change Revenue 40,211 40,745 2-1 1 Europe 16,151 16,682-3 thereof Germany 5,931 5,803 +2 NAFTA 11,743 11,525
More informationCroda International Plc
Croda International Plc 2018 Half Year Results July 2018 Cautionary statement and definitions Cautionary statement This review is intended to focus on matters which are relevant to the interests of shareholders
More informationJBS ENDS 3Q18 WITH NET REVENUE OF R$49.4 BILLION AND ADJUSTED EBITDA OF R$4.4 BILLION. Free cash flow reached R$2.3 billion
Highlights São Paulo, November 13, 2018 JBS S.A. (B3: JBSS3; OTCQX: JBSAY) JBS ENDS WITH NET REVENUE OF R$49.4 BILLION AND ADJUSTED EBITDA OF R$4.4 BILLION Free cash flow reached R$2.3 billion In, net
More informationQ Results. October 29, 2018
Q3 2018 Results October 29, 2018 Forwardlooking Statements This presentation contains a number of forwardlooking statements. Words, and variations of words, such as will, expect, may, should, believe,
More information6 MARCH 2017 FULL YEAR RESULTS
6 MARCH 2017 FULL YEAR RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016 01 THE COLLAGEN CASING COMPANY Global Leader One of the world s leading providers of collagen casings for the processed meats sector Provides
More informationINTERIM RESULTS PRESENTATION Strong start to the year, with a strong order book for the second half of September 2017
INTERIM RESULTS PRESENTATION Strong start to the year, with a strong order book for the second half of 2017 11 September 2017 AGENDA Introduction and highlights John Hornby Financial review David Main
More information14 September Anpario plc (AIM: ANP)
14 September 2016 Anpario plc (AIM: ANP) Anpario plc, the international producer and distributor of natural feed additives for animal health, hygiene and nutrition is pleased to announce its interim results
More informationPreliminary results for the year ended 31 March 2014
Preliminary results for the year ended 31 March 2014 7 May 2014 2014 Experian plc. All rights reserved. Experian and the marks used herein are service marks or registered trademarks of Experian plc. Other
More information2017 RESULTS YEAR ENDED 31 ST DECEMBER Bill Whiteley (Chairman) Nicholas Anderson (Group Chief Executive) Engineering Opportunities
2017 RESULTS YEAR ENDED 31 ST DECEMBER 2017 Bill Whiteley (Chairman) Nicholas Anderson (Group Chief Executive) Obadah Zaher (Research Team Leader) and Jagoda Cieslik (Year in Industry Student, R&D) reviewing
More information9M 2018 RESULTS PRESENTATION
9M 2018 RESULTS PRESENTATION 12.11.2018 9M 2018 RESULTS PRESENTATION DISCLAIMER This presentation (the "Presentation") has been prepared and is issued by, and is the sole responsibility of Telepizza Group,
More informationH Results. July 24, 2018
H1 2018 Results July 24, 2018 1 DISCLAIMER Financial data for 2018 are provided in accordance with IFRS 15 and IFRS 9, effective since January 1, 2018. To ensure a meaningful comparison with 2017, financial
More informationCroda International Plc Q3 IMS November 2014
Croda International Plc Q3 IMS November 2014 Underlying progress accelerates in Q3 Constant currency turnover up 4.0% Consumer Care +4.2% Performance Technologies +8.2% Pharma grade Omega 3 sales to PAR
More informationTegel Group Holdings Limited
Tegel Group Holdings Limited FY17 Full Year Results Presentation 27 June 2017 1 TEGEL GROUP HOLDINGS FY17 RESULTS PRESENTATION Disclaimer This presentation contains summary information about Tegel Group
More informationElectrocomponents plc ANNOUNCEMENT OF INTERIM RESULTS
Electrocomponents plc ANNOUNCEMENT OF INTERIM RESULTS HALF YEAR ENDED 30 SEPTEMBER 2010 12 NOVEMBER 2010 DELIVERING FOR OUR CUSTOMERS Agenda Overview and current trading Ian Mason Financial performance
More informationCOCHLEAR FINANCIAL RESULTS FOR THE SIX MONTHS ENDED DECEMBER 2018
ASX Announcement 19 February 2019 COCHLEAR FINANCIAL RESULTS FOR THE SIX MONTHS ENDED DECEMBER 2018 The business delivered an increase in in sales revenue of 11% and net profit of 16% for the half Reported
More informationBekaert. November 2014
Bekaert Content Bekaert in essence Strategy review Annex: 3 rd quarter trading update 2014 1 st half year results 2014 1 Company profile Industrial company with unique geographic, product and sector exposure
More informationPreliminary Results. 19 May 2015
Preliminary Results 19 May 2015 Group returns to profit growth plus strong customer growth Adjusted profit before tax 1 ( m) Profit growth combined with significant extra investment in USA Group delivers
More informationA X A L T A C O A T I N G S Y S T E M S. Q FINANCIAL RESULTS July 26, 2016
A X A L T A C O A T I N G S Y S T E M S Q2 2016 FINANCIAL RESULTS July 26, 2016 Legal Notices Forward-Looking Statements This presentation and the oral remarks made in connection herewith may contain forward-looking
More informationInvestor & Analyst Presentation
Investor & Analyst Presentation FY18 H1 Results For the six monthsended 31 December 2017 15 th February 2018 Rebekah O Flaherty-CEO I Jonathan Kenny-CFO Agenda 1 2 3 4 5 6 Overview Strategic Priorities
More information2016/17 Half Year Results De La Rue plc 22 November 2016
2016/17 Half Year Results De La Rue plc 22 November 2016 Page 1 Disclaimer This presentation has been prepared by De La Rue plc ( De La Rue ). This presentation includes statements that are, or may be
More informationGood progress across the business. Continuing to deliver growth strategy.
Good progress across the business. Continuing to deliver growth strategy. Frontier Developments plc Interim Results February 2017 1 Introduction Independent creator of videogames founded in 1994 by David
More informationSecond quarter Vestas Wind Systems A/S. Copenhagen, 17 August Classification: Public
Second quarter Vestas Wind Systems A/S Copenhagen, 17 August Classification: Public Disclaimer and cautionary statement This document contains forward-looking statements concerning Vestas financial condition,
More informationCharoen Pokphand Foods Plc.
Charoen Pokphand Foods Plc. 1Q14 RESULTS BRIEFING May 15, 2014 Content Business Overview Q12014 Results Briefing Financial Highlights Future Plan Appendix A: Product & Raw Materials Price Trend B: Product
More informationSABMiller plc. Full year results Twelve months ended 31 March Jamie Wilson, Chief Financial Officer Gary Leibowitz, SVP, Investor Relations
SABMiller plc Full year results Twelve months ended 31 March 2012 Jamie Wilson, Chief Financial Officer Gary Leibowitz, SVP, Investor Relations 24 May 2012 Forward looking statements This presentation
More informationINTRODUCTION STEVE RAWLINS, GROUP CHIEF FINANCIAL OFFICER ANDY BLUNDELL, CHIEF EXECUTIVE TOM PRESTWICH, DIRECTOR, GROUP CHANGE PROGRAMME FEBRUARY 2018
INTRODUCTION ANDY BLUNDELL, CHIEF EXECUTIVE STEVE RAWLINS, GROUP CHIEF FINANCIAL OFFICER TOM PRESTWICH, DIRECTOR, GROUP CHANGE PROGRAMME FEBRUARY 2018 TRADING UPDATE 16/01/18 2 THE BOARD ANTICIPATES THAT
More information2009 Half Year Results. 29 July 2009
1 2009 Half Year Results 29 July 2009 2 Roger Carr Chairman 3 Agenda Chairman s comments Roger Carr First Half Highlights Todd Stitzer Operational and Financial Review Andrew Bonfield Strategic Update
More informationFinancial Information
Financial Information H1 revenues reached 12.8bn up 9.8%, flat org. in Q2 Adj. EBITA reached 1.6bn, up 6.4%, Adj. EBITA margin flat excl. Invensys in a challenging environment 2015 targets: Around flat
More informationFor personal use only
SAI Global Limited Company Update Peter Mullins, Chief Executive Officer May 7 th 2015 ASX:SAI Disclaimer 2 This document has been prepared by SAI Global Limited (SAI) and comprises written materials/slides
More informationCondensed Interim Financial Statements 2018 Tarsus Group plc. Six months ended 30 June quickening the pace SCALE & MOMENTUM
Condensed Interim Financial Statements 2018 Tarsus Group plc Six months ended 30 June 2018 quickening the pace SCALE & MOMENTUM Condensed Interim Financial Statements 2018 Tarsus Group plc Six months
More information2013 Interim Results. 14 August 2013
2013 Interim Results 14 August 2013 1 This presentation contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives.
More informationFull-year results 2017 Conference. February 15, 2018 Nestlé full-year results 2017
Full-year results 2017 Conference 1 Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements involve certain
More informationQ4 & FY 2018 Results. January 30, 2019
Q4 & FY 2018 Results January 30, 2019 This presentation contains a number of forwardlooking statements. Words, and variations of words, such as will, expect, may, believe, estimate, deliver, potential,
More information2017 Interim Results. 14 September 2017
2017 Interim Results 14 September 2017 1 Disclaimer NOT FOR PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT
More informationTWELVE MONTHS END 31 MARCH 2018 MARCO GOBBETTI
TWELVE MONTHS END 31 MARCH 2018 MARCO GOBBETTI CHIEF EXECUTIVE OFFICER 1 AGENDA INTRODUCTION FINANCIAL RESULTS GUIDANCE STRATEGIC UPDATE Q&A FY 2018 HIGHLIGHTS Results in line with our expectations Group
More informationPPG Industries, Inc. Second 2016 Financial Results Earnings Brief July 21, 2016
PPG Industries, Inc. Second 2016 Financial Results Earnings Brief July 21, 2016 Second Quarter 2016 Financial Highlights PPG net sales for the second quarter 2016 were $4.1 billion, down less than one
More informationBofA Merrill Lynch Conference 30 September, Mark Wilson Group CEO
BofA Merrill Lynch Conference 30 September, 2015 Mark Wilson Group CEO 1 Disclaimer Cautionary statements: This should be read in conjunction with the documents filed by Aviva plc (the Company or Aviva
More informationGfi Informatique. H results 05/08/2015. H results 1
Gfi Informatique 1 Agenda I. H1 2015 performance II. Detailed financial results III. Outlook IV. Conclusion 2 Agenda I. H1 2015 performance Vincent Rouaix, Chairman and Chief Executive Officer 3 Highlights
More informationAxalta Coating Systems Ltd.
Q1 2015 Conference Call May 6, 2015 Notice Regarding Forward Looking Statements, Non-GAAP Financial Measures and Defined Terms Forward-Looking Statements This presentation and the oral remarks made in
More information2011 First Quarter Results Jean-Jacques Gauthier
Granulats et Béton - Afrique du Sud, stade Moses Mabhida 2011 First Quarter Results Jean-Jacques Gauthier May 5, 2011 Disclaimer This document may contain forward-looking statements. Such forward-looking
More informationCOCHLEAR FINANCIAL RESULTS FOR YEAR ENDED JUNE 2017
ASX Announcement 17 August 2017 COCHLEAR FINANCIAL RESULTS FOR YEAR ENDED JUNE 2017 Cochlear s market leadership position has strengthened with market growth and market share improvements throughout the
More informationTomTom reports second quarter 2011 results
De Ruyterkade 154 1011 AC Amsterdam, The Netherlands corporate.tomtom.com ir@tomtom.com 22 July 2011 TomTom reports second quarter 2011 results Q2 2011 financial summary Revenue of 314 million compared
More information2013 Full Year Results Presentation 3 March 2014
2013 Full Year Results Presentation 3 March 2014 Wolfhart Hauser Chief Executive Officer Lloyd Pitchford Chief Financial Officer 1 Lloyd Pitchford Chief Financial Officer Financial Performance 2013 Full
More informationPresentation of results for the six months ended 30 th September st November 2017
Presentation of results for the six months ended 30 th September 2017 21 st November 2017 Cautionary statement This presentation contains forward looking statements that are subject to risk factors associated
More informationPreliminary Results 2013 Imperial Tobacco Group PLC
Preliminary Results 2013 Imperial Tobacco Group PLC 5 November 2013 1 Disclaimer Certain statements in this document constitute or may constitute forward-looking statements. Any statement in this document
More information2018 Interim Results 30 August 2018
2018 Interim Results 30 August 2018 Disclaimer Statements in this presentation with respect to each of Total Produce s and Dole Food Company's ("Dole") business, strategies, projected financial figures,
More information2011 Half Year Results 30 th June 2011
2011 Half Year Results 30 th June 2011 Mark Vernon Chief Executive David Meredith Finance Director Overview of Half Year 2011 results 2011 2010 Change Constant currency Revenue 307.7m 277.0m +11% +11%
More informationHalf-yearly results for six months ended 30 September November 2015
Half-yearly results for six months ended 30 September 2015 10 November 2015 2015 Experian plc. All rights reserved. Experian and the marks used herein are service marks or registered trademarks of Experian
More information2012 First-Half Review. Paris - September 5, 2012
2012 First-Half Review Paris - September 5, 2012 Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis.
More informationPRELIMINARY RESULTS 2014 FOR THE YEAR ENDING 31st DECEMBER Tuesday 3rd March 2015
PRELIMINARY RESULTS 2014 FOR THE YEAR ENDING 31st DECEMBER 2014 Tuesday 3rd March 2015 PRELIMINARY RESULTS 2014 HIGHLIGHTS Strong organic revenue growth of 6% Underlying PBT increased by 3% Established
More informationANSELL LIMITED Half Year Results to December Magnus Nicolin Chief Executive Officer Neil Salmon Chief Financial Officer
ANSELL LIMITED Half Year Results to December 2014 Magnus Nicolin Chief Executive Officer Neil Salmon Chief Financial Officer Disclaimer The following presentation has been prepared by Ansell Limited for
More information2017 FULL YEAR RESULTS. February 28,
2017 FULL YEAR RESULTS February 28, 2018 1 Disclaimer This presentation contains both historical and forward-looking statements. These forward-looking statements are based on Carrefour management's current
More informationRPC Group Plc 2015/16 Interim Results
RPC THE ESSENTIAL INGREDIENT RPC Group Plc 101 25 November 2015 Agenda Business Review Promens Update Financial Review Outlook PV FD SK PV 102 FOCUSED GROWTH *Proforma Group at constant exchange rates
More information2013 Full Year Results
2013 Full Year Results Basel: February 5, 2014 Safe harbor This document contains forward-looking statements, which can be identified by terminology such as expect, would, will, potential, plans, prospects,
More information2012 Full Year Results. 27 February 2013
2012 Full Year Results 27 February 2013 Introduction Stephen Harris Chief Executive Induction hardening Used to obtain a hard case for wear resistance or to increase fatigue strength. The induction process
More informationSALES TO 30 SEPTEMBER 2017
SALES TO 30 SEPTEMBER 2017 All growth data specified in this presentation refers to organic growth (constant FX and Group structure), unless otherwise stated. Data may be subject to rounding. This presentation
More informationThird quarter Vestas Wind Systems A/S. Copenhagen, 9 November Classification: Public
Third quarter Vestas Wind Systems A/S Copenhagen, 9 November Classification: Public Disclaimer and cautionary statement This document contains forward-looking statements concerning Vestas financial condition,
More informationFull year results to 30 June 2015 Greg Fitzgerald, Executive Chairman, and Graham Prothero, Finance Director
Full year results to 30 June 2015 Greg Fitzgerald, Executive Chairman, and Graham Prothero, Finance Director FY15 Results Analyst Presentation, 16 September 2015 1 Agenda Overview Strategy to 2018 Financial
More information0 Preliminary Results December Preliminary Results December March 2011
0 Preliminary Results December 2010 Preliminary Results December 2010 23 March 2011 Agenda Introduction 2010 Results International business Acquisition of Atomic PR Citigate Grayling Red Huntsworth Health
More informationFirst half underlying EBIT in line with guidance; business on track to deliver full year earnings growth Highlights
Nufarm Limited ACN 091 323 312 103-105 Pipe Road, Laverton North, VIC Australia 3026 Telephone: (03) 9282 1000 Facsimile: (03) 9282 1002 Postal Address: PO Box 103, Laverton, VIC Australia 3028 21 March,
More information1 of 7 5/5/14 6:46 AM
TYSON POSTS RECORD SECOND QUARTER; SALES EXCEED $9.0 BILLION AS EARNINGS INCREASE 58% TO $0.60 05/05/14 SPRINGDALE, Ark., May 5, 2014 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE:TSN), today reported the
More information